Abstract
Highly active antiretroviral therapy might lead to the development of dyslipidemia and lipodystrophy (LD) syndrome. We carried out a multicenter prospective study of 22 human immunodeficiency virus (HIV)-1-infected children treated during 48 months with lopinavir/ritonavir-based highly active antiretroviral therapy to evaluate the trend of serum lipids and adipokines. Increase in plasma leptin levels and leptin/adiponectin ratio was associated with LD. These adipokines may be surrogate markers of LD.
Publication types
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active / methods
-
Biomarkers
-
Child
-
Child, Preschool
-
HIV Infections / complications*
-
HIV Infections / drug therapy*
-
HIV-1
-
HIV-Associated Lipodystrophy Syndrome / chemically induced*
-
Humans
-
Infant
-
Leptin / blood*
-
Lopinavir
-
Prospective Studies
-
Pyrimidinones / adverse effects*
-
Pyrimidinones / therapeutic use
-
Ritonavir / adverse effects*
-
Ritonavir / therapeutic use
Substances
-
Anti-HIV Agents
-
Biomarkers
-
Leptin
-
Pyrimidinones
-
Lopinavir
-
Ritonavir